Emmaus Life Sciences (NASDAQ:EMMA) CEO Yutaka Niihara purchased 31,100 shares of Emmaus Life Sciences stock in a transaction dated Wednesday, February 12th. The stock was bought at an average price of $1.75 per share, with a total value of $54,425.00.
Yutaka Niihara also recently made the following trade(s):
- On Friday, February 7th, Yutaka Niihara purchased 18,800 shares of Emmaus Life Sciences stock. The stock was bought at an average price of $1.70 per share, with a total value of $31,960.00.
Shares of NASDAQ EMMA opened at $2.77 on Friday. The stock has a market cap of $134.27 million, a PE ratio of -0.25 and a beta of 2.91. Emmaus Life Sciences has a fifty-two week low of $0.95 and a fifty-two week high of $11.76. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.44 and a current ratio of 1.44. The stock has a fifty day moving average of $2.40 and a 200-day moving average of $2.90.
Separately, Zacks Investment Research upgraded Emmaus Life Sciences from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Tuesday, November 5th.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement.
Featured Story: Cryptocurrencies
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.